### Center for Cell Engineering Seventh Annual Retreat

## Celebrating the Opening of the Michael G. Harris Cell Therapy and Cell Engineering Facility

October 21, 2014 2:00 – 5:30 PM Zuckerman Auditorium

#### **SESSION I: STEM CELL THERAPY**

#### **Cell Therapy for Parkinson's Disease**

Lorenz Studer, MD

Director, Center for Stem Cell Biology Developmental Biology Program, MSK

### Clinical Cord Blood Transplantation: Current State of the Art

Juliet N. Barker, MBBS

Director, Cord Blood Transplantation Program Department of Medicine, MSK

## Pluripotent-independent Reprogramming of Endothelial to Hematopoietic Cells by Vascular Induction

Shahin Rafii, MD

Director, Ansary Center for Stem Cell Therapeutics Weill Cornell Medical College

### Globin Gene Transfer for Thalassemia and Sickle Cell Disease

Farid Boulad, MD

Medical Director, Pediatric Day Hospital Department of Pediatrics, MSK

#### **SESSION II: T CELL THERAPY**

### **CAR T Cells**

### The Many Roles of the Cell Therapy and Cell Engineering Facility

Isabelle Rivière, PhD

Director, Cell Therapy and Cell Engineering Facility Molecular Pharmacology & Chemistry Program, MSK

#### **CD19 CAR T Cell Therapy**

Renier Brentjens, MD, PhD

Director, Cellular Therapeutics Center Department of Medicine, MSK

### **Mesothelin CAR T Cell Therapy**

Prasad S. Adusumilli, MD, FACS

Deputy Chief, Thoracic Service Department of Surgery, MSK

### **Enhancing the IQ of CAR T Cells Using the Synthetic Biology Tool Box**

Michael Jensen, MD

Director, Ben Towne Center for Childhood Cancer Research, Seattle Children's Hospital, University of Washington

## The Design of Receptors and Cell Products for Cancer Immunotherapy

**Stanley Riddell, MD** 

Member, Fred Hutchinson Cancer Research Center University of Washington School of Medicine

### **TCR T Cells**

### **Engineering T Cells to Target Oncogenic Proteins: It Starts with the TCR**

Philip Greenberg, MD

Head, Immunology Program, Fred Hutchinson Cancer Research Center University of Washington School of Medicine

# Adoptive Immunotherapy with Transplant Donor or Third Party-derived EBV-specific T-cells for EBV-associated Malignancies

Richard O'Reilly, MD

Chair, Department of Pediatrics Chief, Pediatric Bone Marrow Transplant Service, MSK

#### **CLOSING REMARKS**

Michel Sadelain, MD, PhD

Director, Center for Cell Engineering Immunology Program, MSK

